FDA approves CSL's treatment for hereditary angioedema

The news: Biotech giant CSL has announced that the US Food and Drug Administration (FDA) has approved its new treatment, Andembry, which helps prevent attacks of hereditory angioedema, a rare genetic disorder that causes recurrent and unpredictable swelling in various parts of the body.

The numbers: Andembry will be available for adult and pediatric patients aged 12 years and older.

Hereditory angioedema affects about one in 50,000 people.

The context: CSL said it will launch Andembry in the US immediately, offering the treatment through its third-party specialty pharmacy network before the end of June.

The FDA approval follows other recent approvals for the treatment in Australia, the UK, the European Union, Japan, Switzerland and the United Arab Emirates.